The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports

The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports
The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Published Dec 31, 2009
78 pages — Published Dec 31, 2009
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.' The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global respiratory diseases therapeutics market. The report analyzes the markets for respiratory disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Annualized market data for the respiratory diseases therapeutics market from 2000 to 2008, forecast forward to 2015- Analysis of the leading therapeutic segments including asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension and cystic fibrosis- Analysis of the respiratory diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan - Market characterization of the respiratory diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns - Key drivers and barriers that have a significant impact on the market - Coverage of pipeline molecules in various phases of drug development - Competitive benchmarking of leading companies. The key companies studied in this report are Novartis AG, AstraZeneca and Merck & Co- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global respiratory diseases therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to- Align product portfolio to the markets with high growth potential- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety- Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC007MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents47
1.1 List of Tables63
1.2 List of Figures92
2 Global Respiratory Therapeutics Market : Scope of Research111
2.1 Introduction111
2.2 GBI Research Report Guidance111
3 Global Respiratory Therapeutics Market : Market Characteraization 1211
3.1 Market Forecasts121
3.2 Branded Vs Generics131
3.3 Average Cost of Therapy141
3.4 Volume151
3.5 Usage Patterns161
3.5.1 Diseased Population161
3.5.2 Treatment Seeking Population171
3.5.3 Diagnosed Population 181
3.5.4 Prescription Population 191
3.5.5 Usage Patterns202
Global Revenue Distribution Indication Wise221
4 Global Asthma Therapeutics Market238
4.1 Market Forecasts231
4.2 Average Cost of Therapy241
4.3 Volume251
4.4 Usage Patterns261
4.4.1 Diseased Population261
4.4.2 Treatment Seeking Population271
Diagnosed Population281
4.4.4 Prescription Population281
4.4.5 Usage Patterns292
5 Global COPD Therapeutics Market318
5.1 Market Forecasts311
5.2 Average Cost of Therapy321
5.3 Volume322
5.4 Usage Patterns341
5.4.1 Diseased Population341
5.4.2 Treatment Seeking Population351
5.4.3 Diagnosed Population361
5.4.4 Prescription Population371
5.4.5 Usage Patterns372
Global Pulmonary Arterial Hypertension Therapeutics Market398
6.1 Market Forecasts391
6.2 Volume401
6.3 Average Cost of Therapy411
6.4 Usage Patterns421
6.4.1 Diseased Population421
6.4.2 Treatment Seeking Population431
6.4.3 Diagnosed Population441
6.4.4 Prescription Population451
6.4.5 Usage Patterns452
Global Cystic Fibrosis Therapeutics Market478
7.1 Market Forecasts471
7.2 Volume481
7.3 Average Cost of Therapy491
7.4 Usage Patterns501
7.4.1 Diseased Population501
7.4.2 Treatment Seeking Population511
7.4.3 Diagnosed Population521
7.4.4 Prescription Population531
7.4.5 Usage Patterns532
8 Global Respiratory Therapeutics Market : Market Drivers and Restraints556
8.1 Market Drivers551
8.1.1 Steady Increase in the Smoking Population 551
Stable Increase in Incidence Rates for Respiratory Diseases Disorders561
8.1.3 Increase in Awareness Levels of Disease Progression and Etiology561
8.2 Market Restraints561
8.2.1 Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers561
8.2.2 Reimbursement Restrictions on Drug Classes for Certain Respiratory Diseases Drug Classes Restricts the Market Growth571
8.3 Global Respiratory Therapeutics Market : Unmet Needs571
8.4 Global Respiratory Therapeutics Market: Key Market Trends581
8.5 Increase in Disease Incidence and Prevalence Rates591
8.6 Product Pipeline 591
8.7 Advertising and Commercialization591
8.8 Regulatory Trends Current Reimbursement Scenario591
8.8.1 The Budget Impact on Drug Reimbursements601
8.8.2 Reliability on Generic Formulations as a Cost Cutting Measure601
Global Respiratory Therapeutics Market: Competitive Landscape614
9.1 Overview611
9.2 Market Share Analysis611
9.3 Competitive Profiling621
9.3.1 GlaxoSmithKline 631
9.3.2 AstraZeneca631
9.3.3 Merck631
9.3.4 Boehringer Ingelheim GmbH641
10 Global Respiratory Therapeutics Market : Strategic Consolidations 658
10.1 Mergers and Acquisitions651
10.1.1 Overview652
10.1.1.1 Reckitt Benckiser-Adams Respiratory671
10.1.1.2 Pfizer-Encysive Pharmaceuticals671
10.1.1.3 Novartis-Nektar Therapeutics (Pulmonary Business Unit)671
10.1.1.4 Critical Therapeutics-Cornerstone Biopharma Holdings671
10.2 Licensing Agreements672
10.2.1 Approval 691
10.2.1.1 Alvesco HFA691
10.2.1.2 Curosurf701
10.2.2 Filed701
10.2.2.1 Daxas701
10.2.2.2 Symbicort701
10.2.3 Phase III701
10.2.3.1 Unit Dose Budesonide711
10.2.3.2 Budesonide711
10.2.4 Phase II711
10.2.4.1 AMG317721
10.2.4.2 PTC124721
10.2.5 Pre-clinical721
10.2.5.1 AZD1419721
10.2.6 Discovery 721
10.2.6.1 La Jolla/Med OX 40 Ligand721
11 Global Respiratory Therapeutics Market : Appendix736
11.1 Market Definitions731
11.2 Abbreviations 731
11.3 Research Methodology745
11.3.1 Coverage741
11.3.1.1 Secondary Research741
11.3.1.2 Forecasts751
11.3.1.3 Analogous forecasting methodology751
11.3.1.4 Diseased Population751
11.3.1.5 Treatment Seeking Population761
11.3.1.6 Diagnosis Population761
11.3.1.7 Prescription Population761
11.3.2 Primary Research771
11.3.3 Expert Panels781
11.4 Contact Us781
11.5 Disclaimer781

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" Dec 31, 2009. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-7>
  
APA:
GBI Research Reports. (2009). The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Dec 31, 2009. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-7>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.